More importantly, the antimalarial drug artemisinin was recently shown to exert protective effects in AD pathology via inhibiting the activation of NF-κB and the NLRP3 inflammasome in AD mice [116], further verifying that targeting the NLRP3 inflammasome may offer a crucial intervention for AD progression. The gene discussed is NFKB1; the disease is Alzheimer disease.